Soluble Immune Mediators Regulated by CD163+ Macrophages or CD8+ TILs According to EGFR Mutation Status During Anti-PD-1/L1 Monotherapy for NSCLC

SSRN Electronic Journal 2026 Preprint Open access

Read full text

Authors: Daiki Murata, Koichi Azuma, Kenta Murotani, Akihiko Kawahara, Tomoaki Hoshino

DOI: 10.2139/ssrn.6344767

Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Immune cells in cancer